Search company, investor...
Cybin company logo


Founded Year



Reverse Merger | IPO

Total Raised


About Cybin

Cybin (NEO:CYBN) is a life sciences company that advances psilocybin research and product development for the medical and nutraceutical sectors within legal jurisdictions.

Headquarters Location

100 King St West Suite 5600

Toronto, Ontario, M5X 1C9,


Missing: Cybin's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cybin's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Cybin

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Cybin in 1 CB Insights research brief, most recently on Feb 11, 2021.

Expert Collections containing Cybin

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cybin is included in 2 Expert Collections, including Psychedelics.



247 items


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Cybin Patents

Cybin has filed 1 patent.

The 3 most popular patent topics include:

  • Designer drugs
  • Piperazines
  • Serotonin receptor agonists
patents chart

Application Date

Grant Date


Related Topics




Serotonin receptor agonists, Designer drugs, Prodrugs, Trifluoromethyl compounds, Piperazines


Application Date


Grant Date



Related Topics

Serotonin receptor agonists, Designer drugs, Prodrugs, Trifluoromethyl compounds, Piperazines



Latest Cybin News

Psychedlics Companies Report Strong Research Investment

Nov 22, 2022

In other news Even without revenue, psychedelics companies find financing for ongoing research. The maturing psychedelics industry has watched superstar companies come and go. It happens in nascent industries, especially one aligned with federally illegal substances. But even without any revenue-making product, which is standard operating procedure for most of the top psychedelics companies, there are still some interesting movements by companies to expand research and development, make new discoveries through partnerships, and challenge investors to understand the landscape of winners and losers. Let’s take a look at what’s happening with three psychedelics companies who recently filed earnings reports: Filament Health (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) Filament Health filed its third quarter financial results on Nov. 10. In its announcement, the company highlighted that it extended its cash runway with $2.5 million in fresh financing, freeing up more drug development space and more potential patent accrual. It already as four patents from the Canadian Intellectual Property Office and six patents overall. Patents are gold in the bank for any psychedelics development company and a sure sign of ongoing financial health for the company. Filament is estimated to actually make $100,000 in revenue this quarter (through Dec. 31), the company has been spooking investors with a steady market cap reduction over the year, from a high of $41.98 million in September 2021 to $10.48 million this September. Cybin (NEO: CYBN) (NYSE: CYBN) Cybin filed its financial results for the second quarter of fiscal year 2023 on Nov. 14. The company was able to issue and sell up to an additional $28.9 million of common shares, which allows Cybin to access additional cash for growth opportunities and working capital. Cybin, too, is finding gold in their patent work. They strengthened their drug discovery platform and intellectual property portfolio through multiple licensing arrangements that have broadened the company’s intellectual property reach and created a path for potential future pipeline expansion. Cybin now has access to more than 35 patents and applications through a combination of internal filings and licensing arrangements.

Cybin Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cybin Rank

Cybin Frequently Asked Questions (FAQ)

  • When was Cybin founded?

    Cybin was founded in 2019.

  • Where is Cybin's headquarters?

    Cybin's headquarters is located at 100 King St West, Toronto.

  • What is Cybin's latest funding round?

    Cybin's latest funding round is Reverse Merger.

  • How much did Cybin raise?

    Cybin raised a total of $29.37M.

  • Who are the investors of Cybin?

    Investors of Cybin include Clarmin Explorations.

  • Who are Cybin's competitors?

    Competitors of Cybin include VCENNA and 1 more.

Compare Cybin to Competitors

Mindstate Design Labs Logo
Mindstate Design Labs

Mindstate Design Labs is a preclinical-stage biotechnology company developing psychedelic-inspired therapeutics for intractable mental health conditions.

Alto Neuroscience Logo
Alto Neuroscience

Alto Neuroscience develops brain biomarker-based diagnostic tests and personalized treatments for use in mental health, based on a platform built from data aggregated at scale and artificial intelligence analysis tools. It serves clients in the healthcare sector. The firm was founded in 2019 and is based in Los Altos, California.

Biomind Labs

Biomind Labs is a biotech research and development company that develops pharmaceutical sole and combined formulations of the main natural psychedelic molecules with the aim of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications. It develops pharmaceuticals to treat patients suffering from neurological and psychiatric disorders. It was founded in 2019 and is based in Toronto, Canada.


VCENNA is a Mountain View, California-based biotechnology firm.

Tryp Therapeutics Logo
Tryp Therapeutics

Tryp Therapeutics is a clinical stage drug development company bringing medicine with known safety profiles to diseases with no effective first-line treatments.

Filament Health Logo
Filament Health

Filament Health is focused on exclusively natural psychedelic drug discovery and extraction technology company. The mission of Filament Health (FH) is to get safe, natural psychedelics into the hands of everyone who needs them, as soon as possible, by doing the hard extraction and drug discovery science to unlock their healing potential. With a deep natural psychedelics IP portfolio that is rooted in novel extraction and purification methods, an accomplished botanical extraction management team, a Health Canada psilocybin Dealer’s License, and in-house GMP manufacturing capabilities, the company has built the foundation to support a rapidly growing drug discovery pipeline.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.